Analytical Data
-
Gene name
Cerebellin-2
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IUK8
-
Expression Region
Gln52~Leu224
-
Molecular Weight
49kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cerebellin-2 (Cbln-2) is a member of the cerebellin family of neuropeptides, which plays a crucial role in synaptic transmission and neuronal plasticity, particularly in the cerebellum and other regions of the central nervous system. Its involvement in various neurobiological processes has made Cbln-2 an intriguing target for research, particularly regarding its potential contributions to learning, memory, and motor coordination. Studies have shown that Cbln-2 is essential for the formation and maintenance of synapses, as well as for modulating excitatory neurotransmission. Abnormalities in Cbln-2 expression or function have been linked to various neurological disorders, including autism spectrum disorders and schizophrenia. Recent advances in recombinant protein technology have enabled researchers to produce Cbln-2 in sufficient quantities for functional studies, allowing for deeper investigations into its mechanisms of action. This surge in interest is also fueled by the potential therapeutic applications of Cbln-2 in treating synaptic dysfunction-related conditions. Overall, the study of Cbln-2 recombinant protein not only enhances our understanding of synaptic physiology but also opens avenues for developing novel interventions in neurodevelopmental and neuropsychiatric disorders.
